Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Accumulated Expenses (2016 - 2025)

Fate Therapeutics' Accumulated Expenses history spans 14 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 6.46% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.1 million, down 6.46%, while the annual FY2025 figure was $9.1 million, 6.46% down from the prior year.
  • Accumulated Expenses reached $9.1 million in Q4 2025 per FATE's latest filing, down from $17.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $54.0 million in Q3 2021 to a low of $5.4 million in Q1 2024.
  • Average Accumulated Expenses over 5 years is $25.3 million, with a median of $21.8 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: soared 584.24% in 2021, then plummeted 82.82% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $18.4 million in 2021, then soared by 193.78% to $53.9 million in 2022, then tumbled by 80.41% to $10.6 million in 2023, then dropped by 8.08% to $9.7 million in 2024, then dropped by 6.46% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Accumulated Expenses are $9.1 million (Q4 2025), $17.6 million (Q3 2025), and $18.2 million (Q2 2025).